Lysosomal Exocytosis Releases Pathogenic α -Synuclein Species from Neurons

Ying Xue Xie^{1#}, Nima N. Naseri^{2#}, Jasmine Fels¹, Parinati Kharel¹, Yoonmi Na¹, Jacqueline Burré¹, Manu Sharma^{1*}

¹ Appel Institute for Alzheimer's Research, and Brain & Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.

² Department of Chemistry, University of Pennsylvania, Philadelphia, PA, USA.

# Equal contribution

* Correspondence: mas2189@med.cornell.edu

SUMMARY

Considerable evidence supports the release of pathogenic aggregates of the neuronal protein α -Synuclein (α Syn) into the extracellular space. While this release is proposed to instigate the neuron-to-neuron transmission and spread of α Syn pathology in synucleinopathies including Parkinson's disease, the molecular-cellular mechanism(s) remain unclear. Here we show that pathogenic species of α Syn accumulate within neuronal lysosomes in mouse brains and primary neurons. We then find that neurons release these pathogenic α Syn species via SNARE-dependent lysosomal exocytosis; proposing a central mechanism for exocytosis of aggregated and degradation-resistant proteins from neurons.

INTRODUCTION

Cytoplasmic aggregates of the synaptic protein α Syn are a characteristic feature of multiple neurodegenerative diseases termed "synucleinopathies", including Parkinson disease (PD). Over the course of these age-linked diseases, α Syn assembles into amyloid-type β -sheet rich aggregates, depositing as Lewy bodies and/or Lewy neurites within neurons (Baba et al., 1998; Spillantini et al., 1998; Spillantini et al., 1997). The neuro-anatomical propagation of α Syn pathology is highly stereotyped, and has been defined well-enough to be used in staging PD – originating in the medulla and olfactory bulb, then advancing to the midbrain and basal forebrain, followed by "spread" to the neocortex (Braak et al., 2002; Braak et al., 2003). This observation, combined with detection of extracellular α Syn in human cerebrospinal fluid (El-Agnaf et al., 2003), led to the original conjecture that pathogenic species of α Syn may be transmitted neuron-to-neuron via prion-like permissive templating. Subsequently, in PD patients who had received fetal neuron transplants, appearance of Lewy pathology in the undiseased grafted neurons also pointed to the transmission of α Syn pathology from the surrounding PD-affected neurons (Kordower et al., 2008; Li et al., 2008). These observations were followed by animal studies which confirmed either neuron-to-neuron transmission of α Syn pathology (Desplats et al., 2009), or induction of intraneuronal α Syn pathology by an inoculum of extracellular α Syn fibrils (Luk et al., 2012; Volpicelli-Daley et al., 2011a).

However, unclarity persists in how the cytosolic aggregates are conveyed into the extracellular milieu: Proposed pathway(s) include secretion of α Syn monomers, oligomers and/or larger aggregates inside extracellular vesicles – such as exosomes (Danzer et al., 2012; Emmanouilidou et al., 2010) or microvesicles (Minakaki et al., 2018) – which have been categorized collectively as "unconventional secretion". Other proposed mechanisms include synaptic vesicle release (Yamada and Iwatsubo, 2018), or exocytosis of other types of vesicles (Jang et al., 2010; Lee et al., 2005), exophagy (Ejlerskov et al., 2013), membrane translocation (Ahn et al., 2006), or trafficking of aggregates through tunneling nanotubes (Abounit et al., 2016). Yet, all of these studies have not identified a neuronal organelle that accumulates and then secretes the pathogenic α Syn aggregates, resulting in the current mechanistic gap.

Here, we present our finding that pathogenic α Syn species accumulate within the neuronal lysosomes in mouse brains and in primary neurons, and that these species are released from neurons via SNARE-dependent lysosomal exocytosis.

RESULTS

Pathogenic species of α Syn accumulate within the lysosomes of transgenic α Syn^{A53T} mouse brains

Rapid neurodegeneration and synapse loss in cysteine string protein- α knockout mice (CSP α ^{-/-}) is rescued by transgenic expression of α Syn carrying the PD mutation A53T (Tg- α Syn^{A53T}) (Chandra et al., 2005). However, beyond 5 months, the rescued Tg- α Syn^{A53T}/CSP α ^{-/-} mice begin exhibiting neurodegeneration due to the transgenic overexpression of α Syn^{A53T}. Curiously, we found that Tg- α Syn^{A53T}/CSP α ^{-/-} mice have accelerated accumulation of the pathogenic versions of α Syn compared to Tg- α Syn^{A53T}/CSP α ^{+/-} mice, detectable by phospho-Ser129 specific, filamentous α Syn-specific, and amyloid-specific antibodies (**Supplementary Fig. S1**). CSP α ^{+/-} mice have normal CSP α function (Fernández-Chacón et al., 2004), and there was no change in monomeric α Syn levels (**Supplementary Fig. S1**). This suggested that brains of Tg- α Syn^{A53T}/CSP α ^{-/-} mice are collecting α Syn aggregates faster in the absence of CSP α .

Loss-of-function mutations in CSP α cause the lysosomal storage disorder adult-onset neuronal ceroid lipofuscinosis (ANCL) or Kufs disease (Benitez et al., 2011; Cadieux-Dion et al., 2013; Nosková et al., 2011; Velinov et al., 2012). Specifically, loss of CSP α function leads to progressive accumulation of lysosomes containing undegraded material such as lipofuscin/residual bodies, in ANCL patient brains (Benitez et al., 2011), in CSP α ^{-/-} mouse brains (Fernández-Chacón et al., 2004), in *Drosophila* models carrying the ANCL mutations (Imler et al., 2019), and in ANCL patient-derived induced neurons (Naseri et al., 2020). Tg- α Syn^{A53T}/CSP α ^{-/-} mice also accrue lysosomal proteins such as Lamp1 and cathepsin-L, as well as ATP5G – a mitochondrial protein characteristically stored in lysosomes of CSP α loss-of-function models and ANCL patient neurons (**Supplementary Fig. S1**). The enhanced accumulation of lysosomal contents in Tg- α Syn^{A53T}/CSP α ^{-/-} brains, together with the exaggerated buildup of α Syn aggregates in these brains gave us the clue that α Syn aggregates may be depositing in the lysosomes.

We next aimed to determine whether α Syn aggregates accumulate within lysosomes, even in the absence of CSP α ^{-/-}-driven lysosomal pathology. Thus, we tested whether aged Tg- α Syn^{A53T} mice, which display severe α Syn-driven pathology, have α Syn aggregates within their lysosomes.

We found pathogenic α Syn species, but not monomeric α Syn, in dextranosomes (heavy lysosomes loaded with dextran to enhance purity) isolated from the brains of 6 month old Tg- α Syn^{A53T} mice (**Fig. 1 a-c**). These lysosomal fractions precisely coincided with pathogenic α Syn species, and had highly enriched lysosomal proteins as well as cathepsin-D activity, with negligible contamination from other organelle protein-markers or mitochondrial and peroxisomal enzyme activities (**Fig. 1 a-c**). This experiment indicates that isolated intact lysosomes from aged Tg- α Syn^{A53T} mice contain pathogenic α Syn species.

Pathogenic species of α Syn accumulate within the lumen of neuronal lysosomes

The lysosomes studied above are a mixture of lysosomes from all brain cells. To isolate and study lysosomes specifically from neurons, we generated transgenic mice expressing ^{HA}Lamp1^{Myc} – lysosomal protein Lamp1 epitope-tagged

on its luminal domain with tandem 2xHA, and on its cytoplasmic tail with 2xmyc – driven by the neuron-specific synapsin-I promoter (**Supplementary Fig. S2 a-d**), enabling affinity-isolation of neuronal lysosomes from mouse brains. The Tg-^{HA}Lamp1^{Myc} mice were then crossed to the Tg- α Syn^{A53T} mice to generate Tg- α Syn^{A53T}/Tg-^{HA}Lamp1^{Myc} progeny (**Supplementary Fig. S3 a-g**). Immuno-isolation experiments from aged Tg- α Syn^{A53T}/Tg-^{HA}Lamp1^{Myc} mouse brains indicated that pathogenic versions of α Syn co-isolate with neuronal lysosomes (**Fig 2a**). We found that ~10% of the SDS-resistant α Syn aggregates, and ~20% of the more mature α Syn aggregates (filamentous and amyloid-type) reside within neuronal lysosomes (**Fig. 2a**). This result indicates that a non-trivial portion of pathogenic α Syn species in the brain are found in neuronal lysosomes.

To understand the fate of these lysosomal α Syn aggregates, we developed a neuronal model which accumulates pathogenic α Syn species. Compared to Tg- α Syn^{A53T} mice, homozygous Tg- α Syn^{A53T} mice (Tg^{x2}- α Syn^{A53T}), which express twice the amount of transgenic α Syn^{A53T}, have shorter lifespans, earlier onset of neuromuscular pathology, and begin accumulating pathogenic α Syn species earlier – by only 6 weeks of age (**Suppl. Fig. S4 a-f**) – which is achievable in long-lived primary neuron cultures. Accordingly, primary neurons from Tg^{x2}- α Syn^{A53T} mice also accrued pathogenic α Syn species by 6 weeks, including aggregates detectable by antibodies against α Syn fibrils and amyloid-type conformations (**Suppl Fig. S4g**).

To specifically label and track the pathogenic α Syn species located within neuronal lysosomes, we targeted Apex-2 to the lysosomal lumens of Tg^{x2}- α Syn^{A53T} primary neurons. We lentivirally expressed a synapsin-1 promoter-driven construct, comprised of Apex-2 fused to the luminal domain of a truncated version of Lamp1 (^{Apex-2}Lamp1) (**Suppl Fig. S5 a-c**), which proximity-labels the luminal contents of neuronal lysosomes with biotin. In these Tg^{x2}- α Syn^{A53T} neurons expressing ^{Apex-2}Lamp1, we found that pathogenic α Syn species as well as lysosomal proteins (typified by cathepsin-L) were biotinylated (**Fig. 2b**), confirming that pathogenic α Syn species accumulate within the lumen of neuronal lysosomes.

Pathogenic α Syn species are secreted from neurons via SNARE-dependent lysosomal exocytosis

Release of α Syn from neurons, particularly the seeding-competent pathogenic versions of α Syn, is considered a key step in the spatial progression of synucleinopathies (Peng et al., 2020), and α Syn has been documented in extracellular fluids of human PD patients (El-Agnaf et al., 2003). We also found pathogenic species of α Syn in the cerebrospinal fluid of aged Tg- α Syn^{A53T} mice (**Suppl. Fig. S6**). Importantly, this extracellular pool of α Syn species appears not to be enveloped in membranes, as they were not protected from proteinase K digestion (**Suppl. Fig. S6**). Proteolytic susceptibility was also unaffected by the presence of detergent, akin to the lysosomal luminal protein cathepsin-L and the constitutively secreted neuronal protein neuroserpin (**Suppl. Fig. S6**). This was contrary to the well-protected contents of exosomes, typified by TSG101, which becomes susceptible to proteolysis only in the presence of detergent (**Suppl. Fig. S6**). Accumulation inside lysosomes of the pathogenic α Syn species, together with their un-enveloped presence in the extracellular space, prompted us to investigate whether lysosomes are releasing α Syn aggregates contained inside them.

We thus collected the medium from Tg^{x2}- α Syn^{A53T} primary neurons, in which the lysosomal contents had been biotinylated via neuron-specific expression of ^{Apex-2}Lamp1 (as in **Fig. 2b** and **Suppl. Fig. S5**). We found that lysosomal contents, typified by cathepsin-L, as well as pathogenic α Syn species could be precipitated from the medium via their biotin-

modification (**Fig. 3a**). In contrast, exosomal contents, typified by TSG101, were not biotinylated/precipitated. This result points to lysosomal exocytosis – SNARE-dependent fusion of lysosomes with the plasma membrane – as the likely mechanism for the exit of α Syn aggregates from neurons.

To test this hypothesis, we modulated the SNARE proteins responsible for lysosome-to-plasma membrane fusion. First, we found VAMP7 as the prominent v-SNARE in immunisolated lysosomes (**Suppl. Fig. S7a**). We then screened for the Qb-type t-SNAREs which interact and thus co-immunoprecipitate with VAMP7. SNAP23 was the clearest Qb/t-SNARE candidate (**Suppl. Fig. S7a**). Based on these results and prior studies validating them (Rao et al., 2004), we tested four strategies to disrupt lysosomal exocytosis: shRNA knockdown of either SNAP23 (SNAP23^{KD}) or VAMP7 (VAMP7^{KD}), and overexpression of dominant negative fragments of either SNAP23 (SNAP23^{DN}) or VAMP7 (VAMP7^{DN}). In wild type primary neurons, the release of cathepsin-L was used to signal lysosomal exocytosis, opposed to the constitutively secreted neuroserpin. VAMP7^{KD} and SNAP23^{DN} had no significant effect on lysosomal exocytosis, but VAMP7^{DN} severely reduced it by ~80% and SNAP23^{KD} partially reduced it by ~40% (**Suppl. Fig. S7 b-c**). Therefore, we applied the latter two strategies to disrupt lysosomal exocytosis next.

Importantly, in Tg^{x2}- α Syn^{A53T} neurons, both VAMP7^{DN} and SNAP23^{KD} strategies reduced the release of pathogenic α Syn species into the medium, and the effect of SNAP23^{KD} was rescued by overexpression of a knockdown-resistant version of wild type SNAP23 (**Fig. 3b**). Moreover, the release of pathogenic α Syn species was significantly correlated with the change in lysosomal exocytosis, measured as cathepsin-L released into the medium (**Fig. 3 b-c**). These results suggest that SNARE-dependent exocytosis of lysosomes is essential and rate-determining for the release of pathogenic α Syn species from neurons.

α Syn species released via lysosomal exocytosis can seed aggregation of purified recombinant α Syn

Pathogenic spread requires that the released α Syn is able to template or “seed” the assembly of amyloid-type aggregates from monomeric α Syn. To test whether the pathogenic α Syn species exocytosed from neurons are seeding-competent, we performed *in vitro* aggregation of purified recombinant myc-tagged wild type α Syn (**Suppl. Fig. S8**), in the presence of extracellular media collected from neuron cultures generated either from wild type mice, or from Tg^{x2}- α Syn^{A53T} mice with or without lentiviral expression of VAMP7^{DN} fragment (**Fig. 4 a-c**). Aggregation kinetics, measured by amyloid-binding fluorescent dye K114 (**Fig. 4a**) or Thioflavin-T (**Fig. 4b**), were enhanced by medium from Tg^{x2}- α Syn^{A53T} neurons, compared to the medium from wild type neurons. Suppressing lysosomal exocytosis in the Tg^{x2}- α Syn^{A53T} neurons, via VAMP7^{DN} expression, diminished the aggregation-promoting effect of the Tg^{x2}- α Syn^{A53T} medium (**Fig. 4 a-b**). When myc- α Syn aggregation kinetics were measured by quantitative immunoblotting for either disappearance of α Syn monomers or for the appearance of filamentous and amyloid-type aggregates, we again found that compared to the wild type neuron medium, aggregation was augmented by the Tg^{x2}- α Syn^{A53T} medium, and the expression of VAMP7^{DN} fragment diminished this effect (**Fig. 4c**). In all the assays, a lag-time of nearly 2 weeks is apparent before the appearance of amyloid signal with the wild type medium (**Fig. 4a-c**). Importantly, this lag is shortened or eliminated by the aggregates in Tg^{x2}- α Syn^{A53T} medium (**Fig. 4a-c**), with a reduced effect when lysosomal exocytosis is suppressed by VAMP7^{DN} fragment (**Fig. 4a-c**). This seeding activity of the lysosomally released α Syn species indicates that they are capable of amyloid-nucleation via permissive templating.

DISCUSSION

Release of α Syn aggregates from neurons is thought to transmit neuropathology to other yet-unaffected neurons. Here we find that pathogenic α Syn species accumulate within neuronal lysosomes in mouse brains and in primary neurons, and are then released from neurons via SNARE-dependent lysosomal exocytosis.

It is important to note that for α Syn pathology to transmit from neuron-to-neuron, the lysosomal exocytosis mechanism is more in line with the following observations, which underline that the extracellular pool of pathogenic α Syn is likely not membrane-enveloped as in exosomes, extracellular vesicles, or nanotubes, but is non-enveloped: a) the stark pathology and rapid propagation caused by inoculated pre-formed fibrils (Luk et al., 2012; Luk et al., 2009; Paumier et al., 2015; Rey et al., 2018; Rey et al., 2013; Volpicelli-Daley et al., 2011b), b) the efficacy of humoral and cellular immunotherapy against α Syn (reviewed in (Chatterjee and Kordower, 2019)), c) the efficacy of passive immunization using antibodies against α Syn epitopes (reviewed in (Chatterjee and Kordower, 2019)), and d) much of the extracellular α Syn has been found as non-enveloped (Borghi et al., 2000; El-Agnaf et al., 2003; Sung et al., 2005), while a minority of α Syn is contained in extracellular vesicles or exosomes (Ejlertsen et al., 2013; Emmanouilidou et al., 2010; Jang et al., 2010).

Key gaps still remain in how the pathogenic α Syn species are targeted and trafficked to lysosomes, as well as in the fate of extra cellular α Syn aggregates following their release from neurons:

The aggregates/fibrils of α Syn could form inside the acidified lumen of lysosomes (Buell et al., 2014), either from smaller oligomers or monomers, especially if their degradation is delayed due to reduced/disrupted lysosomal activity (Malik et al., 2019). Yet, we found no presence of α Syn monomers within isolated lysosomes, making this possibility less likely. In contrast, macro-autophagy of ready-formed aggregates from the cytoplasm, termed “aggrephagy”, is a more likely mechanism, following from the well-recorded ability of autophagosomes to encapsulate large cytoplasmic structures including aggregates (Yamamoto and Simonsen, 2011), and target them to lysosomes.

Once released from the neurons, the fate of extracellular/interstitial α Syn aggregates also remains unclear, and can follow multiple possible scenarios: uptake into microglia (Lee et al., 2008), astrocytes (Loria et al., 2017), and/or oligodendrocytes (Reyes et al., 2014), and/or drainage via glymphatics (Rasmussen et al., 2018; Smith and Verkman, 2018) or blood-flow (El-Agnaf et al., 2003; Foulds et al., 2013). However, for the extracellular α Syn aggregates to cause the stereotypic “spread” of pathology via a prion-like etiology, other neurons will have to take up the released aggregates, and this process remains even less understood than the glial uptake or clearance scenarios.

The results presented here provide evidence of the accumulation of pathogenic α Syn species in neuronal lysosomes, and pinpoint to lysosomal exocytosis as a pathway of release for these pathogenic α Syn species into the extracellular milieu. This pathway, at first sight, appears to have relevance to the release of undegraded aggregates composed of other proteins as well that transmit pathology from cell-to-cell (reviewed in (Peng et al., 2020)), and follow-up studies will be needed to test this speculation.

FIGURES & LEGENDS

Figure 1 | Pathogenic α Syn aggregates accumulate within lysosomes of aged Tg- α Syn^{A53T} mice.

Lysosomes were isolated from 6 month old Tg- α Syn^{A53T} mouse brains via Percoll gradient centrifugation of the heavy organelle fraction – which contained peroxisomes, heavy lysosomes loaded *in vivo* with dextran-70, and mitochondria swollen *ex vivo* by CaCl_2 . (a) Lysosome (dextranosome) enrichment was determined by immunoblotting for markers of indicated organelles, compared to the respective levels in the total lysate input. (b) Left panels – Activities of enzymes contained within lysosomes (cathepsin-D), mitochondria (citrate synthase), and peroxisomes (catalase) were measured, testing for isolation of intact organelles. Right panel – Summary graph of enzyme activity present in the combined “lysosomal

fractions" (fractions 8-10). **(c)** Top panels – Levels in each Percoll gradient fraction of pathogenic α Syn species: aggregated (α Syn Aggr), aggregates phosphorylated at Ser129 (α Syn^{pSer129} Aggr), amyloid-type (α Syn^{Amyl}), and filamentous (α Syn^{Fila}). Bottom panel – Summary graph of these α Syn species present in the combined "lysosomal fractions" (fractions 8-10). (n=3). **(b-c)** All data in are shown as means $\pm$ SEM, where 'n' represents mouse brains.

Figure 2 | Pathogenic αSyn species accumulate within neuronal lysosomes in mouse brains and primary neurons.

(a) Neuronal lysosomes immunoisolated from the brains of 1 and 6 month old *Tg-αSyn^{A53T}/Tg-^{HA}LAMP1^{Myc}* mice using anti-myc antibody were analyzed by immunoblotting for levels of αSyn, αSyn^{pSer129}, α-Syn^{Fila}, and αSyn^{Amyl} (Mono = monomer, Aggr = aggregates). Fraction of these αSyn species residing within the lysosomes at 6 months of age (bottom graph); this was back-calculated from the fraction of each αSyn species immuno-captured, normalized to the fraction of neuronal lysosomes captured – indicated by the fraction of ^{HA}Lamp1^{Myc} captured. Immunoblots against markers of lysosomes and of other organelles are also shown (n=8). (b) *Tg^{x2}-αSyn^{A53T}* primary cultures lentivirally expressing a synapsin-1 promoter-driven ^{Apex-2}Lamp1 construct were subjected to proximity-labeling with biotin at 14 or 49 days *in vitro* (DIV). Labeled proteins were precipitated on streptavidin-coated magnetic beads and immunoblotted for the indicated pathogenic αSyn species, as well as for marker proteins cathepsin-L (lysosomes), TSG101 (exosomes), synaptogyrin-1 (synaptic vesicles), neuroserpin (constitutively secreted neuronal protein), and β-actin (cytosol) (representative of n=3). Data represent means ± SEM. Each 'n' corresponds to independently aged mouse littermates in (a) and independent primary neuron cultures in (b). ****P<0.0001 by RM 1-way ANOVA with Dunnett multiple-comparison correction; and ###P<0.001; ####P<0.0001 by non-parametric Friedman test with Dunn's multiple-comparison adjustment.

Figure 3 | Pathogenic αSyn species are secreted from neurons via SNARE-dependent lysosomal exocytosis.

(a) *Tg^{x2}-αSyn^{A53T}* primary neurons lentivirally expressing a synapsin-1 promoter-driven *Apex-2Lamp1* (infected on DIV 7) were subjected to proximity-labeling on DIV 47. Biotinylated proteins released into the media during 48 h (by DIV 49) were precipitated on streptavidin-magnetic beads and immunoblotted for the indicated αSyn species (αSyn, αSyn^{pSer129}, αSyn^{Amyl}, and αSyn^{Fila}), lysosome luminal protein cathepsin-L, and exosome luminal protein TSG101. Strept. PPT. = streptavidin precipitate. (representative of n=3). **(b)** Media collected over 2 days (DIV 47-49) from *Tg^{x2}-αSyn^{A53T}* primary neurons lentivirally expressing control (GFP), GFP-VAMP7^{DN} fragment, SNAP23^{KD} shRNA, and SNAP23^{KD} shRNA plus knockdown-resistant SNAP23 rescue-construct (infected on DIV 7), were immunoblotted for the indicated αSyn species (αSyn, αSyn^{pSer129}, αSyn^{Amyl}, and αSyn^{Fila}), cathepsin-L (lysosome luminal), neuroserpin (constitutively secreted from neurons), and β-actin (cytoplasmic). For quantification (graphs on the right) protein level in medium was normalized to its levels in total cellular lysate (5% loaded) (n=7). **(c)** Correlation between the levels of pathogenic αSyn species and the levels of cathepsin-L released in the medium, upon the indicated manipulation of SNARE-dependent lysosomal exocytosis; derived from data shown above in panel (b). Linear regression is shown with dotted lines depicting the 95% confidence intervals, and Pearson's correlation coefficient is indicated on the bottom right of each graph. (n=7). All data represent means ± SEM. Each 'n' corresponds to a separate mouse litter used for a batch of neuronal culture and infection. In **(b)** *P<0.05; **P<0.01; ***P<0.001; by RM 1-way ANOVA with Dunnett multiple-comparison correction; and #P<0.05; ##P<0.01; ###P<0.001 by non-parametric Friedman test with Dunn's multiple-comparison adjustment.

Figure 4 | Seeding of recombinant αSyn aggregation by pathogenic αSyn species exocytosed from neurons.

(a-c) Recombinant purified myc-αSyn was shaken at 37°C in presence of concentrated extracellular medium from mouse cortical neuron cultures collected over 7 days (DIV 42-49), generated either from wild type (WT) mice, or from Tg^{x2}-αSyn^{A53T} mice with or without lentiviral expression of VAMP7 dominant-negative fragment (VAMP7^{DN}; infected at DIV 7). Aggregation of myc-αSyn was analyzed at the indicated days of incubation by the following assays: (a) Congo-red derivative, amyloid-binding dye K114 fluorescence at 390/535 nm (n=4). (b) Amyloid-binding dye Thioflavin-T fluorescence at 450/485 nm (n=4). (c) Quantitative immunoblotting for the myc epitope-tag, where aggregation is measured as disappearance of monomeric myc-αSyn (top; n=4); dot-blotting for filamentous myc-αSyn aggregates using αSyn^{Fila} antibody (middle; n=4); and dot-blotting for amyloid-type myc-αSyn aggregates using αSyn^{Amyl} A11 antibody (bottom; n=4). All data represent means ± SEM, where each 'n' is an independent aggregation experiment. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 by RM 2-way ANOVA.

Supplementary Figure S2 | Development of a transgenic mouse model to isolate neuronal lysosomes from brains.

(a) ^{HA}Lamp1^{Myc} construct lentivirally expressed via neuron-specific synapsin-1 promoter (schematics on left), localizes in neurons marked by Map-2 (and not in surrounding glia seen in DAPI panel), and co-localizes with the lysosomal protein Lamp2 in primary neuron cultures (immunofluorescence in middle panels). Expression of full length protein ^{HA}Lamp1^{Myc} is confirmed by immunoblotting for its epitope tags: N-terminal HA tag and C-terminal myc tag. (b) This lentiviral vector was used to generate Tg-^{HA}Lamp1^{Myc} mice via pronuclear injection of linearized DNA comprising the synapsin-1 promoter and the ^{HA}Lamp1^{Myc} cDNA. (c) Tg-^{HA}Lamp1^{Myc} mice were PCR-genotyped using primer-pairs at the N- and the C-terminal ends of the ^{HA}Lamp1^{Myc} cDNA. Single insertion-site for the transgene was suggested by equal numbers of WT and Tg-^{HA}Lamp1^{Myc} pups born per litter (n=11 litters). There was also no effect of the transgene on birth-ratio and growth (indicated by weight gain; n=5 per group) of the Tg-^{HA}Lamp1^{Myc} mice compared to WT mice. (d) Immunoblots show that ^{HA}Lamp1^{Myc} protein is detectable in mouse brains by immunoblots against the N-terminal HA tag and the C-terminal myc tag. All data represent means ± SEM. n.s. = not significant, by 2-tailed Student's t-test for littermate ratio and by RM 2-way ANOVA for weight gain over age. *Note*: Further characterization of the Tg-^{HA}Lamp1^{Myc} mice is included in **Supplementary Fig. S3**.

Supplementary Figure S3 | In Tg-αSyn^{A53T}/Tg-HA^{Lamp1}^{Myc} double-transgenic mice, the neuromuscular impairments driven by αSyn^{A53T} transgene remain unaffected by the HA^{Lamp1}^{Myc} transgene.

(a) Tg-αSyn^{A53T} mice were crossed to Tg-HA^{Lamp1}^{Myc} mice to generate the Tg-αSyn^{A53T}/Tg-HA^{Lamp1}^{Myc} progeny. (b) Equal numbers of pups with the four resultant genotypes (WT, Tg-HA^{Lamp1}^{Myc}, Tg-αSyn^{A53T}, and Tg-αSyn^{A53T}/Tg-HA^{Lamp1}^{Myc}) were born from crossing Tg-αSyn^{A53T} and Tg-HA^{Lamp1}^{Myc} parents (n=9 litters). Tg-αSyn^{A53T}/Tg-HA^{Lamp1}^{Myc} and Tg-αSyn^{A53T} mice were indistinguishable in (c) lifespan, as well as in the onset and course of neuromuscular deterioration (d-g): Signs of progressive neuromuscular debility preceded death, as measured by (d) onset of hind-limb clasping, (e) grid-hang (limb strength), (f) T-turn on pole-test (bradykinesia), and (g) descent on pole test (motor coordination) (n=10 mice per group). (f-g) Mice that died were scored as 20 s (maximum measurement) for the rest of the trial – not as an actual measurement, but as a place holder. The same data are shown in the lighter shaded graphs without the 20 s placeholder, as dead animals are eliminated from the cohort over time. WT and Tg-HA^{Lamp1}^{Myc} mice showed no impairments in these measurements (n=5 mice per group). (b and f-g) Data represent means ± SEM. n.s. = not significant, by RM 1-way ANOVA in (b), Log-rank (Mantel-Cox) test for comparisons of Kaplan-Meier curves (c-e), RM 2-way ANOVA (dark shaded graphs) and mixed-effects analysis (lighter shaded graphs) for pole turn and pole descent test (f-g).

Supplementary Figure S4 | Characterization of the homozygous Tg^{x2}-αSyn^{A53T} mice and primary neurons.

(a) Doubling the dose of αSyn^{A53T} in Tg^{x2}-αSyn^{A53T} mice resulted in accelerated mortality, nearly halving the lifespan of Tg-αSyn^{A53T} mice. This is accompanied by accelerated onset of neuromuscular impairment in Tg^{x2}-αSyn^{A53T} mice, as measured by (b) onset of hind-limb clasping, (c) onset of grid-hang impairment (limb strength) (d) T-turn on pole-test (bradykinesia), and (e) descent on pole test (motor coordination). WT mice showed no impairments during the time course (n=10 Tg-αSyn^{A53T}; n=13 Tg^{x2}-αSyn^{A53T}; n=6 WT mice). (d-e) Mice that died were scored as 20 s (maximum measurement) for the rest of the trial – not as an actual measurement, but as a place holder. The same data are shown in the lighter shaded graphs without the 20 s placeholder, as dead animals are eliminated from the cohort over time. (f) In addition to increased levels of αSyn monomer, αSyn aggregates are detected in Tg^{x2}-αSyn^{A53T} brains much earlier than in Tg-αSyn^{A53T} brains. (g) Tg^{x2}-αSyn^{A53T} primary neuron cultures recapitulate the accelerated accumulation of pathogenic αSyn species. (a-c)

*** $P < 0.001$ and **** $P < 0.0001$ by Log-rank (Mantel-Cox) test. (**d-e**) Data represent means $\pm$ SEM, ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$ by RM 2-way ANOVA (dark shagged graphs) and mixed-effects analysis (lighter shaded graphs); analysis between Tg^{x2}- α Syn^{A53T} and Tg- α Syn^{A53T} is up to 6 mo.

Supplementary Figure S5 | Generation of ^{Apex-2}Lamp1 chimeric protein for labeling lysosomal luminal proteins in primary neurons.

(a) Apex-2 was fused to the N-terminus of truncated Lamp1, and expressed via neuron-specific synapsin-1 promoter, allowing it to biotinylate lysosomal luminal proteins. (b) Lentivirally expressed ^{Apex-2}Lamp1 (infected on DIV 7, immunostained on DIV14) co-localizes with lysosomal protein Lamp2 in primary neurons. Neuronal somal and dendrites are marked by Map2. (c) Expression of ^{Apex-2}Lamp1 in primary neurons is confirmed by immunoblotting for its epitope tags: N-terminal FLAG and C-terminal myc.

Supplementary Figure S6 | Extracellular α Syn species in cerebrospinal fluid are not membrane-enveloped.

Cerebrospinal fluid (CSF) collected from 6 month old Tg- α Syn^{A53T} mice were subjected to limited proteolysis using indicated concentrations of proteinase K (PK) in the absence or presence of 0.1% Triton X-100. Immunoblots for α Syn protein levels (α Syn^{pSer129}, α Syn^{Amyl}, and α Syn^{Fila}), cathepsin-L, TSG101, and neuroserpin (n=4). All data represent means $\pm$ SEM. Each 'n' is an independent proteolysis experiment. ***P<0.001; ****P<0.0001 by RM 2-way ANOVA and Bonferroni post-test with multiple hypothesis correction.

Supplementary Figure S7 | SNARE-dependence of lysosomal exocytosis.

(a) From *Tg-HA*LAMP1^{Myc} mouse brains, we immunoisolated lysosomes (as in Fig. 2), followed by immunoblotting for the indicated vSNAREs (left panel). From wild type mouse brains, we immunoprecipitated (IP) VAMP7 and immunoblotted for the indicated co-IP'd Qb motif containing tSNAREs (middle panel). We then performed the inverse IP, where SNAP23 was IP'd and VAMP7 co-IP was tested by immunoblotting (right panel) (representative of $n=3$). (b) In WT neurons, shRNA knockdown constructs VAMP7^{KD} and SNAP23^{KD} were lentivirally expressed (Control = virus without shRNA), followed by quantitative immunoblotting of VAMP7 and SNAP23 levels ($n=4$). Secreted levels of lysosome luminal protein cathepsin-L and the constitutively secreted protein neuroserpin were also quantified from the medium, and normalized to β -actin quantified from the respective culture lysate ($n=4$). (c) In WT neurons, dominant-negative constructs GFP-VAMP7^{KD} and GFP-SNAP23^{KD} were lentivirally expressed (Control = virus without shRNA), followed by quantitative immunoblotting of VAMP7 and SNAP23 levels ($n=4$). Secreted levels of lysosome luminal protein cathepsin-L and the constitutively secreted protein neuroserpin were also quantified from the medium, and normalized to β -actin quantified from the respective culture lysate ($n=4$).

SNAP23^{KD} were lentivirally expressed (Control = GFP), followed by immunoblotting for GFP (representative of n=4). Quantification of cathepsin-L and neuroserpin in the medium, normalized to β -actin in cell lysates (n=4). All data represent means $\pm$ SEM. Each 'n' is an independent immunoisolation/immunoprecipitation in **(a)** and an independently infected neuron culture in **(b-c)**. In **(b-c)** **P<0.01; ***P<0.001; ****P<0.0001 by RM 1-way ANOVA with Dunnett multiple-comparison correction; and #P<0.05 by non-parametric Friedman test with Dunn's multiple-comparison adjustment.

Supplementary Figure S8 | Recombinant myc-αSyn.

Purified recombinant myc-αSyn protein separated by SDS-PAGE, followed by Coomassie brilliant blue staining, as well as immunoblotting against myc and αSyn.

METHODS

Mouse lines and husbandry

Mice were housed with a 12 h light/dark cycle in a temperature-controlled room with free access to water and food. Animal husbandry and the experimental protocols used in this study were approved by the Institutional Animal Care and Use Committee (IACUC) at Weill Cornell Medicine.

CSP α knockout mice rescued by transgenic α Syn^{A53T} expression.

Transgenic mice that express α Syn^{A53T} under the control of Thy-1 promoter (Chandra et al., 2005) were crossed to CSP α knockout mouse line (Fernández-Chacón et al., 2004) by breeding Tg- α Syn^{A53T} to CSP α ^{+/-} mice. The early neurodegeneration and death of CSP α ^{-/-} mice was rescued by overexpressing α Syn^{A53T} (Chandra et al., 2005). Rescued Tg- α Syn^{A53T}/CSP α ^{-/-} mice were bred with CSP α ^{+/-} mice to obtain littermate CSP α ^{+/-} and CSP α ^{-/-} mice that either express or lack α Syn^{A53T} transgene. CSP α ^{+/-} mice have no CSP α loss of function phenotype. Both, Tg- α Syn^{A53T} and CSP α ^{-/-} mouse lines are available from Jackson Laboratory: B6.Cg-Tg(THY1-SNCA^{A53T})M53Sud/J (stock # 008135) and B6.129S6-Dnajc5tm1Sud/J (stock # 006392), respectively.

Generation of Tg-^{HA}Lamp1^{Myc} mice.

The transgenic mice were derived from a lentiviral vector. The lentiviral vector included truncated synapsin-1 promoter followed by ORF including Lamp1 signal sequence - 2xHA epitope tag – rat Lamp1 – 6His – TEV cleavage site - 2xMyc epitope tag. This lentivirus vector was digested overnight at 37°C with PacI and SphI to create a 3.45 kb linear fragment for pronuclear microinjection. The cleavage product included truncated 5' LTR, the promoter and ^{HA}Lamp1^{Myc} ORF (as described above), WPRE, and part of the bGH poly(A) signal. The enzymes were heat inactivated at 65°C for 20 minutes and the 3.45 kb band was purified/extracted using the Qiaquick gel extraction kit. The pronuclear injection was performed at Cornell University Stem Cell & Transgenic Core Facility into B6(Cg)-Tyrc-2J/Jx FVB embryos. 115 embryos were injected, and 76 embryos proceeded to the 2-cell stage. Of the 18 clones born, 2 positive clones (male founders 1 and 7) contained PCR-detectable full length ^{HA}Lamp1^{Myc}, followed by confirmation by immunoblotting for protein expression. The founder transgenic clones were bred to wild type female C57BL/6 mice. The genotyping primers amplify sequences either near the N-terminal end (F: 5'-CGCGACCATCTGCGCTG-3' and R: 5'-GCTGTGCCGTTGTTGTC-3'; product = 297 bp), or near the C-terminal end (F: 5'-GCACATCTTTGTGAGCAAGGCG-3' and R: 5'-GCAATAGCATGATACAAAGGC-3; product = 474 bp) of the insert.

Crossing Tg- α Syn^{A53T} mice with Tg-^{HA}Lamp1^{Myc} mice.

Neuron-specific ^{HA}Lamp1^{Myc} transgenic mice were crossed to Tg- α Syn^{A53T} mice, and bred either as single transgenics (Tg-^{HA}Lamp1^{Myc} to Tg- α Syn^{A53T}) or bred as Tg- α Syn^{A53T}/Tg-^{HA}Lamp1^{Myc} double-transgenic to wild type. Either breeding-scheme produced Mendelian 25% Tg- α Syn^{A53T}/Tg-^{HA}Lamp1^{Myc} and 25% wild type progeny, and 25% progeny carrying each transgene alone; indicating single copy or insertion site for each transgene, carried on distinct chromosomes.

Lysosome (dextranosome) isolation from mouse brains via density gradient centrifugation

Enrichment of dextran-loaded lysosomes (dextranosomes), enhanced by mitochondrial swelling, was based on previously published techniques (Arai et al., 1991; Graham, 2001). Mice were anesthetized with isoflurane and intracranially injected with 10 μ l dextran-70 (250 mg/ml) into each cortex. 36 h later, mice were terminally anesthetized and perfused with homogenization buffer (HM = 10 mM HEPES buffer pH 7.0 with 0.25 M sucrose and 1 mM EDTA). The brain was dissected out, washed with HM and homogenized in 1.5 ml HM. Homogenate was centrifuged at 340 g_{av} for 5 min, any floating fat layer was aspirated, pellet discarded, and the supernatant was re-centrifuged at 340 g_{av} for 5 min. The resultant post-nuclear supernatant was incubated with 1 mM $CaCl_2$ for 5 min at 37°C to swell the mitochondria, in order to reduce mitochondrial contamination in the dextranosomal fractions. This solution was centrifuged at 10,000 g_{av} for 30 min to precipitate heavy organelles. The pellet containing swollen mitochondria, peroxisomes and dextranosomes was resuspended in 1 ml HM and layered over 9 ml of 27% v/v Percoll in 0.25 M sucrose, followed by centrifugation at 35,000 g_{av} for 90 min, to generate the Percoll gradient. 1 ml fractions were collected from top, with dextranosomes expected near the bottom of the gradient. Fractions were centrifuged at 100,000 g_{av} at for 1 h to pellet the Percoll particles. The supernatant above the Percoll pellet was concentrated using Amicon (10 kDa cutoff), and assayed.

Assays for cathepsin-D, citrate synthase, and catalase activity

Activities of enzymes contained within the lysosomes (cathepsin-D), mitochondria (citrate synthase), or peroxisomes (catalase) were measured from the Percoll gradient fractions dissolved in 0.1% Triton X-100 (final). Cathepsin-D activity was assayed using ab65302 kit (Abcam) according to the manufacturer's protocol. Each fraction was incubated with the cathepsin-D substrate GKPIFFRLK(Dnp)-D-R-NH₂ labeled with MCA at 37°C for 1 h in the dark. Fluorescence was measured at Ex: 328 nm, Em: 460 nm, in a solid white 96-well plate (Costar). Citrate synthase activity was assayed using ab239712 kit (Abcam) according to the manufacturer's protocol, and absorbance at 412 nm was measured in clear bottom 96-well plate (Costar). Catalase activity was assayed using ab83464 kit (Abcam) according to the manufacturer's protocol, and absorbance at 570 nm was measured in clear bottom 96-well plate (Costar). Synergy H1 Hybrid Reader was used for all three enzyme assays.

Neuromuscular behavior tests and survival study

Pole test. The pole test was performed based on the method established by Ogawa et al. (Ogawa et al., 1985). Animals were positioned with their head upward near the top of a wooden dowel (1 cm in diameter and 50 cm high). The time taken until they turned completely downward (defined as a "T-turn", indicative of bradykinesia) and time taken after the T-turn to descend to the bottom (indicative of motor coordination) were recorded. All animals were trained three times before performing the test. The maximum time allowed for each measurement was 20 s. If the animal could not turn, or fell during descent, the experiment was repeated; and if the animal again could not turn or fell during descent, the time for the activity was recorded as the maximum 20 s. **Grid hang test.** As in (Burré et al., 2010), animals were placed on top of a wire mesh grid (1.27 cm x 1.27 cm). The grid was then shaken lightly to cause the mouse to grip the wires with all four limbs, and then turned upside down. The mesh was held approximately 20 cm above the home cage litter, high enough to prevent the mouse of easily climbing down but not to cause harm in the event of a fall. A stopwatch was used to record the time taken by the animal to fall off the grid. Three trials per mouse were performed with a 1 min inter-trial interval. The highest time of the 3 trials was assigned as the time for each animal to fall. After a maximum hang time of 120 s, mice

were removed from the grid. *Hind limb clasp*ing. Mice were lifted by tail for 20 s. If an animal retracted its hind limbs toward the abdomen and held them there, it was scored positive for hind limb clasp. *Survival study*. End point for survival study was reaching neuromuscular debility (e.g. paresis) which could make it difficult for the animal to get to food or water. At that time, the animal was euthanized according to the approved protocols.

Immuno-isolation of lysosomes from mouse brains

Immunoprecipitation was used to isolate lysosomes from Tg^{-HA}Lamp1^{Myc} mouse brains. Mouse brains were lysed in PBS without detergent and supplemented with EDTA-free protease inhibitor cocktail (Thermo Fisher). The post-nuclear supernatant was incubated with anti-myc magnetic beads (with covalently cross-linked clone 9E10 mAb; Pierce) for 2 h at 4 °C, followed by 3 washes in PBS. The precipitated material was eluted in non-reducing 2x Laemmli sample buffer at room temperature, followed by immunoblotting.

Mouse CSF collection and limited proteolysis

6 month old Tg- α Syn^{A53T} mice were terminally anesthetized with isoflurane, and CSF was collected by exposing cisterna magna (Lim et al., 2018), and using syringe aspiration (Hamilton 10 μ l syringe). Samples with visible signs of blood were discarded. Following CSF collection, the mice were secondarily euthanized by cervical dislocation and brain collected for unrelated experiments. Due to low and/or variable volume of CSF collected in different attempts, multiple littermate mice were tapped and the CSF was pooled prior to proteolysis experiments.

Fresh pooled CSF at room temperature was aliquoted into 2 equal portions, and equal volume of either PBS or PBS containing Triton X-100 (0.1% final) was added to each tube and incubated for 10 min. Samples were then mixed with equal volume of Proteinase K (0, 1, 10, or 100 μ g/ml final) from 100x stocks in sterile water, and incubated for 1 h at 15 °C (to minimize membrane permeability). Proteolysis was immediately stopped by adding 5x Laemmli sample buffer with PMSF (1 mM final), followed by immunoblotting.

Immunoprecipitation

For co-immunoprecipitation of SNARE proteins, brain homogenate was lysed in PBS containing 0.1% Triton X-100 and supplemented with EDTA-free protease inhibitor cocktail (ThermoFisher). Postnuclear supernatant was incubated for 2 h at 4 °C with the antibody, and then for another 1 h following the addition of protein-G Sepharose (GE Healthcare). Protein bound to antibody beads was washed five times with lysis buffer at 4 °C, and eluted in 2x Laemmli sample buffer. Eluent was boiled for 20 min to disassemble SNARE complexes, followed by immunoblotting.

Long term primary neuron culture from Tg^{2x}- α Syn^{A53T} mice

Primary cultures were based on modification of our neuron culture protocol (Naseri et al., 2020) with published procedures for long term cultures (Lesuisse and Martin, 2002). Neonatal (P0) cerebral cortices were isolated and dissected in cold HBSS. Cortices were dissociated by trypsinization (0.05% trypsin-EDTA for 10 min at 37 °C), triturated with a siliconized pipette and plated onto poly-L-lysine-coated 24-well plastic dishes at high density (800-1000 cells/mm²; each experiment

had the same cell density across plates), in DMEM (Invitrogen) supplemented with 5% horse serum (Invitrogen) and 1% penicillin-streptomycin (Life Technologies). Humidity was enhanced by adding autoclaved water in spaces between the wells, and the plates were not disturbed for at least 5 days. On day 5-7, medium was changed to serum-free neurobasal medium (Life Technologies) supplemented with 2% B27 (Life Technologies) or N21-MAX (R&D Systems), and neurons were infected at the same time with lentiviruses. 50% of the medium was changed every 7 days. Neuronal cultures were maintained for up to 7 weeks (DIV 49).

Tg^{2x}-αSyn^{A53T} mouse breeders were derived from Tg-αSyn^{A53T} mice crossed to each other. However, this line was difficult to breed due to short survival and unreliable breeding output. Alternatively, we cultured cortices from all of the pups from either Tg-αSyn^{A53T} parents, or from Tg^{2x}-αSyn^{A53T} male bred with Tg-αSyn^{A53T} females (harem breeding). The pups were tested for homozygosity by cerebellar immunoblots against αSyn. Only Tg^{2x}-αSyn^{A53T} cultures were maintained through to the DIV 5 steps of medium replacement and lentiviral infection.

Media from 49 day old neurons was spun through 5 um mini strainer (pluriselect) to exclude any debris, followed by concentration on 10 kDa Amicon (Millipore).

Lentivirus production and transduction

HEK293T cells were co-transfected with the lentiviral vector plasmid, with the HIV-1 lentiviral packaging constructs pRSVREV and pMDLg/pRRE (Dull et al., 1998), and the vesicular stomatitis virus-G expression plasmid pHCMVG (Yee et al., 1994). The virus-containing culture supernatant was collected 48 h post-transfection and was concentrated by centrifugation at 50,000 g for 90 min. The viral pellet was resuspended in neuronal medium (at 1/10 of the pre-centrifugation volume). All lentiviruses used in a single experiment were prepared together. Neurons were infected on DIV 5-7, and harvested for experiments at times described in figure captions.

Immunofluorescence in neurons

For immunofluorescent labeling of cortical neuron cultures, cells on coverslips were washed with PBS + 1 mM MgCl₂ and fixed in 4% paraformaldehyde for 30 min at room temperature. Cells were permeabilized for 5 min in PBS + 0.1% Triton X-100, and blocked for 20 min in PBS + 5% BSA (blocking buffer). Coverslips were then incubated in primary antibodies in blocking buffer overnight at 4 °C. Following five washes, coverslips were incubated with secondary antibodies labeled with Alexa 488 and/or Alexa 546 (Life Technologies) in blocking buffer containing DAPI, for 1–2 h, followed by five PBS washes and mounting on slides in Fluormount G (ThermoFisher). Images were acquired on a Nikon H550L microscope.

SNARE shRNA knockdown and dominant-negative strategies

Once VAMP7 and SNAP23 were identified as cognate lysosomal SNAREs, in agreement with prior studies (Rao et al., 2004), we modulated their function via shRNA knockdown and dominant-negative strategies: Based on pre-characterized target sequences and hairpins described on the Broad Institute Genetic Perturbation Platform, mouse VAMP7 and

SNAP23 shRNAs were cloned into L309 lentiviral vector to be expressed under human H1 promoter. For VAMP7, the target sequence was 5'-TTACGGTTCAAGAGCACAAAC-3', and for SNAP23, the target sequence was 5'-CAACCGAGCCG-GATTACAAAT-3'. Rescue expression of human SNAP23 from FUW vector (Lois et al., 2002) was not affected by the anti-mouse shRNA target sequence.

To express a dominant negative VAMP7 fragment, rat VAMP7/TI-VAMP truncated at the C-terminal end (Ala²-Asn¹²⁰ fragment expressed) (Martinez-Arca et al., 2000) was expressed as an eGFP chimera (GFP-VAMP7²⁻¹²⁰) via FUGW lentiviral vector (Lois et al., 2002).

To generate a dominant negative version of SNAP23, the last eight residues of human SNAP23 were deleted (Asp²-Ala²⁰³ segment expressed) mimicking the dominant negative SNAP25¹⁻¹⁹⁷ fragment generated by Botulinum toxin-A cleavage (Huang et al., 1998) and expressed as an eGFP chimera (GFP-SNAP23²⁻²⁰³) from FUGW lentiviral vector (Lois et al., 2002).

Proximity-labeling of lysosomal contents

To target Apex-2 to the lysosomal lumen, Apex-2 was fused at the N-terminus to the transmembrane domain of rat Lamp1. The ^{Apex-2}Lamp1 construct consists of: Lamp1 signal sequence - Flag tag - APEX2 - rat Lamp1 truncation including transmembrane domain plus C-terminal cytosolic tail with lysosome-targeting motif (Lamp1³⁷⁰⁻⁴⁰⁷ including the targeting motif ⁴⁰³GYQTI⁴⁰⁷) - 6His - TEV - Myc tag, generating a 36 kDa protein.

^{Apex-2}Lamp1 was lentivirally expressed via a truncated synapsin-1 promoter in Tg^{x2}-αSyn^{A53T} primary neurons by infection on DIV7. On DIV 49, cells were incubated at 37°C for 1 h in medium containing 500 μM biotin tyramide, plus a lysosomal pH-raising cocktail (10 nM NH₄Cl and 100 nM Bafilomycin A1) to enhance the reaction. H₂O₂ was added at a final concentration of 1 mM for exactly 1 min at room temperature. Reaction was quenched for 30 sec with PBS + 1mM MgCl₂ containing antioxidants (5 mM Trolox, 10 mM ascorbic acid). Cells were washed with PBS + 1mM MgCl₂, and lysed in PBS + 0.1% Triton-X 100, and biotinylated proteins were precipitated on streptavidin-magnetic beads (Dynabeads; Thermo), with 3 washes before elution in 2x Laemmli sample buffer.

To chase biotin-labeled proteins, Tg^{x2}-αSyn^{A53T} primary neurons lentivirally expressing ^{Apex-2}Lamp1, were subjected to biotin labeling on DIV 47, similar to above, except using 0.5 mM H₂O₂ to reduce toxicity. The reaction was quenched with 37°C medium containing antioxidants (5 mM Trolox, 10 mM sodium ascorbate, and 5 mM glutathione). 10 minutes later, the medium was replaced, containing 2.5 mM glutathione. 48 h later, the culture-medium was collected, and biotinylated proteins were precipitated on streptavidin-magnetic beads (Dynabeads; Thermo), with 3 washes before elution in 2x Laemmli sample buffer.

Purification and in vitro aggregation of recombinant myc-αSyn

Recombinant myc-αSyn was expressed and purified essentially as in (Burré et al., 2015). Full-length human αSyn cDNA containing an N-terminal myc epitope-tag was inserted into a modified pGEX-KG vector (GE Healthcare), after a TEV protease recognition site to allow cleavage from GST (myc-αSyn contains an extra N-terminal glycine after cleavage with

TEV protease). BL21 strain of *E. coli* bacteria transformed with this plasmid were grown to optical density 0.6 (at 600 nm), and protein expression was induced with 0.05 mM isopropyl β -D-thiogalactoside (IPTG) for 6 hours at room temperature. Bacteria were pelleted by centrifugation for 20 min at 4000 rpm, and then resuspended in solubilization/lysis buffer, PBS containing 0.5 mg/ml lysozyme, 1 mM PMSF, DNase, and an EDTA-free protease inhibitor mixture (Roche). Bacteria were further broken by sonication, and insoluble material was removed by centrifugation for 30 min at 7000 g_{av} at 4°C. Protein was affinity-bound to glutathione Sepharose beads (GE Healthcare) by incubation overnight at 4°C, followed by TEV protease (Invitrogen) cleavage for 6 hours at room temperature. The His-tagged TEV protease was removed by incubation with Ni-NTA (Qiagen) overnight at 4°C. Protein concentration was assessed using the bicinchoninic acid (BCA) assay (Thermo Fisher Scientific).

For the aggregation studies, 10 μ l of concentrated extracellular medium from neuronal cultures – collected over 7 days (DIV 42-49), spun through 5 μ m strainer (Puriselect), and concentrated 10x using 10 kDa cutoff Amicon (Millipore) – was added to 40 μ l of recombinant myc- α Syn (to 4 μ g/ μ l final concentration) in PBS with protease inhibitors. This mixture was incubated at 37°C with shaking at 300 rpm, while sample aliquot were taken at indicated time periods and frozen at -80°C. At the end of final incubation time-point, all the samples were thawed and measured together.

5 μ l of sample was mixed with 95 μ l of 100 μ M K114 (Santa Cruz Biotechnology) in 100 mM glycine-NaOH, pH 8.45, and K114 fluorescence was measured at Ex: 390 nm, Em: 535 nm, in a solid white 96-well plate (Costar) using a plate reader (Synergy H1 Hybrid Reader, BioTek). Thioflavin-T measurement was done similarly, by mixing 5 μ l sample with 95 μ l of 25 μ M Thioflavin-T (Sigma) in PBS, pH 7.4, and fluorescence was measured at Ex: 450 nm, Em: 485 nm. After fluorometry, the same samples were dissolved in Laemmli sample buffer and used for SDS-PAGE or dot blots, followed by immunoblotting.

SDS-PAGE and quantitative immunoblotting

For SDS-PAGE, 10-15% Laemmli gels (10.3%T and 3.3%C) were used to separate proteins on Bio-Rad apparatus. 1 mM final DTT was used in SDS Laemmli buffer. Proteins were transferred onto nitrocellulose (pore-size = 0.45 μ m; GE Healthcare) and blocked with 5% w/v fat-free dry milk in tris buffered saline, pH 7.5 supplemented with 0.1% Tween 20 (TBS-T). Immunoblotting was performed by incubating the blocked membranes with primary antibodies in blocking buffer for 8-16 hours. Following 5 washes with TBS-Tween 20 (0.1%). Blots were incubated with secondary antibodies (goat anti-rabbit conjugated to IRDye 600RD or 800CW; LI-COR) at 1/5000 in blocking buffer for 1-3 hours. Immunoblots were washed 5x with TBS-T and dried, then scanned on Odyssey CLx (LI-COR) and quantified using Image-Studio software (LI-COR).

For ATP5G immunoblots, following the transfer, nitrocellulose membranes were dried and fixed for 15 min at room temperature in 1% paraformaldehyde in PBS (Ikegaki and Kennett, 1989). Membranes were then washed 3x with TBS-T and treated as above.

For dot blots, samples were dotted onto dry nitrocellulose membrane (if sample volume <5 μ l) or on a PBS wetted nitrocellulose membrane under vacuum (if volume was >5 μ l), and allowed to dry. The membrane was then immunoblotted as above.

Antibody list

β -Actin: Sigma (A1978); A11 oligomers: Stressmarq (SPC-506D); ATP5G: Abcam (ab181243); Calreticulin: Thermo Fisher (OTI15F5) and Novus (NB600-103); Cathepsin-L: Novus (JM10-78); CD81: Novus (SN206-01); EEA1: Thermo Fisher (MA5-14794); Flag: Sigma Cl. M2 (F3165); GAPDH: Cell Signaling Cl. 14C10 (2118); GFP: Takara Cl. JL8 (632381) and Invitrogen (A11122); GluN2B/NR2B: Cell Signaling Cl. D15B3 (4212); GOSR1: Abcam (ab53288); GOSR2: ProteinTech (12095-1-AP); HA epitope: Abcam Cl. 16B12 HA.11 (ab130275); Histone H3: Cell Signaling Cl. 96C10 (3638); Hsp60: Abcam (ab5479); Lamp-1: DSHB Cl. H4A3 and Cl. 1D4B DSHB Rat mono; Lamp-2: Cl. ABL-93 DSHB Rat mono; Map-2: Millipore (AB5622); Myc epitope: DSHB Cl. 9E10 and Sigma (C3956); Na/K-ATPase: DSHB Cl. A6F; NeuN: Millipore Cl. A60 (Mab377); Neuroserpin: Abcam (ab33077); Pex3: Thermo Fisher (PA5-37012); Pex13: Sigma (ABC143); Sec22b: SYSY (186 003); Sec22c: Novus (NBP1-30760); Sec22L2: MyBiosource.com (MBS8507611); SNAP23: Santa Cruz (sc-166244) and Sudhof lab P914; SNAP25: Biolegend Cl. SM181 (836304) and Sudhof lab P913; SNAP29: SYSY (111303); SNAP47: SYSY (111403); synaptogyrin-1: SYSY (103 002); α Syn: BD Transduction (610787) and Sudhof Lab T2270; α Syn filamentous (α Syn^{Fila}): Abcam Cl. MJFR-14-6-4-2 (ab209538); α Synuclein Ser129 phosphorylated (α Syn^{pSer129}): Abcam (ab51253); TGN38: BD Transduction (610899); TIM23: BD Transduction (611223); TSG101: Abcam (ab125011); α -Tubulin: DSHB Cl. 12G10; VAMP1: SYSY (104 002); VAMP2: SYSY (104 202); VAMP5: SYSY (176 003); VAMP7/TiVAMP: SYSY (232 011) and SYSY (232 003); VAMP8: SYSY (104 302); VTI1A: SYSY (165 002); VTI1B: SYSY (164 002); Ykt6: Abcam (ab241382).

Statistical analyses

Each “n” consisted of reagents produced in parallel (e.g., purified proteins, lentivirus production, culturing neurons, brain or CSF harvested from mice euthanized together) and experiments performed in parallel (e.g. lentiviral infection, sample collection for immunoprecipitation and immunoblotting, mouse behavior recorded on same day etc.). Experiments were quantified using parametric as well as non-parametric statistical tests when warranted (see the tests described below and in figure captions). Randomization and coding of mice or samples was done by different investigator(s) than the investigator who did quantification and analysis. All analyses are performed using GraphPad Prism 8 and described in the figure legends. Column analyses of data with more than 2 groups depicted in bar graphs (e.g. α Syn species in lysosomal fractions and α Syn species in extracellular media) were analyzed by repeated measures (RM) 1-way ANOVA with Dunnett multiple-comparison correction, as well as using the non-parametric Friedman test with Dunn’s multiple-comparison adjustment. For comparison of only two groups (e.g. such as for littermate ratio of WT and Tg-^{HA}Lamp1^{Myc} cross) 2-tailed Student’s t-test was used. For time-course experiments (e.g. accumulation of α Syn over age and seeding of recombinant α Syn) the curves were analyzed using RM 2-way ANOVA in comparing the overall curve, plus the Bonferroni post-test with multiple hypothesis correction to compare data at each time-point independently or to examine more than two groups. Graphs depicting the correlation (e.g. between the levels of pathogenic α Syn species released versus the levels of cathepsin-L released in the medium) were analyzed via Pearson’s correlation and shown with linear regression lines, as well as the 95% confidence interval using dotted lines. Kaplan-Meier curves (e.g. survival, onset of hind-limb clasping, and onset of grid-hang impairments) were compared via Log-rank (Mantel-Cox) test. For vertical pole studies, due to decreasing sample size with each mouse death, two separate curves were graphed to represent each of the pole-turn and the pole-descent data. Mice that died were scored as 20 s (maximum measurement) for rest of the trial – not as an actual measurement, but as a place

holder. Data with 20 s placeholder were analyzed by RM 2-way ANOVA and data without the 20 s placeholder were analyzed via mixed effects analysis.

ACKNOWLEDGEMENTS

We thank Dr. Tom Südhof for kindly sharing the CSP α knockout and Tg- α Syn^{A53T} mouse lines, as well as antibodies against α Syn, SNAP-23, and SNAP-25.

FUNDING

This work was supported by NIH F31 studentship (NS098623, to N.N.N.), grants from Alzheimer's Association (NIRG-15-363678 to M.S.), American Federation for Aging Research (New Investigator in Alzheimer's Research Grant, to M.S.), NIH National Institute for Neurological Disorders and Stroke (1R01NS102181 and 1R01NS113960, to J.B.; and 1R01NS095988, to M.S.), NIH National Institute for Aging (1R01AG052505, to M.S.).

AUTHOR CONTRIBUTIONS

Y.X.X., N.N.N., J.F., P.K., Y.N., J.B., and M.S. designed, performed and analyzed all experiments. Y.X.X., N.N.N., J.B., and M.S. wrote the manuscript. M.S. conceived the project and directed the research.

COMPETING INTERESTS

The authors declare no competing interests.

REFERENCES

- Abounit, S., Bousset, L., Loria, F., Zhu, S., de Chaumont, F., Pieri, L., Olivo-Marin, J.C., Melki, R., and Zurzolo, C. (2016). Tunneling nanotubes spread fibrillar α -synuclein by intercellular trafficking of lysosomes. *The EMBO journal* 35, 2120-2138.
- Ahn, K.J., Paik, S.R., Chung, K.C., and Kim, J. (2006). Amino acid sequence motifs and mechanistic features of the membrane translocation of alpha-synuclein. *J Neurochem* 97, 265-279.
- Arai, K., Kanaseki, T., and Ohkuma, S. (1991). Isolation of highly purified lysosomes from rat liver: identification of electron carrier components on lysosomal membranes. *J Biochem* 110, 541-547.
- Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q., and Iwatsubo, T. (1998). Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. *The American journal of pathology* 152, 879-884.
- Benitez, B.A., Alvarado, D., Cai, Y., Mayo, K., Chakraverty, S., Norton, J., Morris, J.C., Sands, M.S., Goate, A., and Cruchaga, C. (2011). Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis. *PLoS One* 6, e26741.
- Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., Abbruzzese, G., and Tabaton, M. (2000). Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. *Neurosci Lett* 287, 65-67.
- Braak, H., Del Tredici, K., Bratzke, H., Hamm-Clement, J., Sandmann-Keil, D., and Rüb, U. (2002). Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). *J Neurol* 249 Suppl 3, III/1-5.
- Braak, H., Del Tredici, K., Rüb, U., de Vos, R.A.I., Jansen Steur, E.N.H., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiology of aging* 24, 197-211.
- Buell, A.K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles, T.P., Linse, S., and Dobson, C.M. (2014). Solution conditions determine the relative importance of nucleation and growth processes in α -synuclein aggregation. *Proc Natl Acad Sci U S A* 111, 7671-7676.
- Burré, J., Sharma, M., and Südhof, T.C. (2015). Definition of a Molecular Pathway Mediating α -Synuclein Neurotoxicity. *J Neurosci* 35, 5221-5232.
- Burré, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R., and Südhof, T.C. (2010). Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. *Science* 329, 1663-1667.
- Cadieux-Dion, M., Andermann, E., Lachance-Touchette, P., Ansorge, O., Meloche, C., Barnabé, A., Kuzniecky, R.I., Andermann, F., Faught, E., Leonberg, S., et al. (2013). Recurrent mutations in DNAJC5 cause autosomal dominant Kufs disease. *Clin Genet* 83, 571-575.

- Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O.M., and Südhof, T.C. (2005). Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. *Cell* 123, 383-396.
- Chatterjee, D., and Kordower, J.H. (2019). Immunotherapy in Parkinson's disease: Current status and future directions. *Neurobiol Dis* 132, 104587.
- Danzer, K.M., Kranich, L.R., Ruf, W.P., Cagsal-Getkin, O., Winslow, A.R., Zhu, L., Vanderburg, C.R., and McLean, P.J. (2012). Exosomal cell-to-cell transmission of alpha synuclein oligomers. *Molecular neurodegeneration* 7, 42.
- Desplats, P., Lee, H.-J., Bae, E.-J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., Masliah, E., and Lee, S.-J. (2009). Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. *Proceedings of the National Academy of Sciences of the United States of America* 106, 13010-13015.
- Dull, T., Zufferey, R., Kelly, M., Mandel, R.J., Nguyen, M., Trono, D., and Naldini, L. (1998). A third-generation lentivirus vector with a conditional packaging system. *Journal of virology* 72, 8463-8471.
- Ejlertskov, P., Rasmussen, I., Nielsen, T.T., Bergstrom, A.L., Tohyama, Y., Jensen, P.H., and Vilhardt, F. (2013). Tubulin polymerization-promoting protein (TPPP/p25alpha) promotes unconventional secretion of alpha-synuclein through exophagy by impairing autophagosome-lysosome fusion. *J Biol Chem* 288, 17313-17335.
- El-Agnaf, O.M.A., Salem, S.A., Paleologou, K.E., Cooper, L.J., Fullwood, N.J., Gibson, M.J., Curran, M.D., Court, J.A., Mann, D.M.A., Ikeda, S.-i., *et al.* (2003). Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology* 17, 1945-1947.
- Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S.D., Ntzouni, M., Margaritis, L.H., Stefanis, L., and Vekrellis, K. (2010). Cell-produced alpha-synuclein is secreted in a calcium-dependent manner by exosomes and impacts neuronal survival. *J Neurosci* 30, 6838-6851.
- Fernández-Chacón, R., Wölfel, M., Nishimune, H., Tabares, L., Schmitz, F., Castellano-Muñoz, M., Rosenmund, C., Montesinos, M.L., Sanes, J.R., Schneggenburger, R., *et al.* (2004). The synaptic vesicle protein CSP alpha prevents presynaptic degeneration. *Neuron* 42, 237-251.
- Foulds, P.G., Diggle, P., Mitchell, J.D., Parker, A., Hasegawa, M., Masuda-Suzukake, M., Mann, D.M., and Allsop, D. (2013). A longitudinal study on α -synuclein in blood plasma as a biomarker for Parkinson's disease. *Scientific reports* 3, 2540.
- Graham, J.M. (2001). Isolation of lysosomes from tissues and cells by differential and density gradient centrifugation. *Current protocols in cell biology Chapter 3*, Unit 3.6.
- Huang, X., Wheeler, M.B., Kang, Y.H., Sheu, L., Lukacs, G.L., Trimble, W.S., and Gaisano, H.Y. (1998). Truncated SNAP-25 (1-197), like botulinum neurotoxin A, can inhibit insulin secretion from HIT-T15 insulinoma cells. *Molecular endocrinology (Baltimore, Md)* 12, 1060-1070.
- Ikegaki, N., and Kennett, R.H. (1989). Glutaraldehyde fixation of the primary antibody-antigen complex on nitrocellulose paper increases the overall sensitivity of immunoblot assay. *Journal of immunological methods* 124, 205-210.

- Imler, E., Pyon, J.S., Kindelay, S., Torvund, M., Zhang, Y.Q., Chandra, S.S., and Zinsmaier, K.E. (2019). A *Drosophila* model of neuronal ceroid lipofuscinosis CLN4 reveals a hypermorphic gain of function mechanism. *Elife* 8.
- Jang, A., Lee, H.J., Suk, J.E., Jung, J.W., Kim, K.P., and Lee, S.J. (2010). Non-classical exocytosis of alpha-synuclein is sensitive to folding states and promoted under stress conditions. *J Neurochem* 113, 1263-1274.
- Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., and Olanow, C.W. (2008). Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. *Nature medicine* 14, 504-506.
- Lee, H.J., Patel, S., and Lee, S.J. (2005). Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. *J Neurosci* 25, 6016-6024.
- Lee, H.J., Suk, J.E., Bae, E.J., and Lee, S.J. (2008). Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. *Biochem Biophys Res Commun* 372, 423-428.
- Lesuisse, C., and Martin, L.J. (2002). Long-term culture of mouse cortical neurons as a model for neuronal development, aging, and death. *Journal of neurobiology* 51, 9-23.
- Li, J.-Y., Englund, E., Holton, J.L., Soulet, D., Hagell, P., Lees, A.J., Lashley, T., Quinn, N.P., Rehncrona, S., Björklund, A., *et al.* (2008). Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. *Nature medicine* 14, 501-503.
- Lim, N.K., Moestrup, V., Zhang, X., Wang, W.A., Møller, A., and Huang, F.D. (2018). An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice. *Journal of visualized experiments : JoVE*.
- Lois, C., Hong, E.J., Pease, S., Brown, E.J., and Baltimore, D. (2002). Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. *Science* 295, 868-872.
- Loria, F., Vargas, J.Y., Bousset, L., Syan, S., Salles, A., Melki, R., and Zurzolo, C. (2017). α -Synuclein transfer between neurons and astrocytes indicates that astrocytes play a role in degradation rather than in spreading. *Acta Neuropathol* 134, 789-808.
- Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J.Q., and Lee, V.M. (2012). Pathological α -synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. *Science* 338, 949-953.
- Luk, K.C., Song, C., O'Brien, P., Stieber, A., Branch, J.R., Brunden, K.R., Trojanowski, J.Q., and Lee, V.M. (2009). Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. *Proc Natl Acad Sci U S A* 106, 20051-20056.
- Malik, B.R., Maddison, D.C., Smith, G.A., and Peters, O.M. (2019). Autophagic and endo-lysosomal dysfunction in neurodegenerative disease. *Mol Brain* 12, 100.
- Martinez-Arca, S., Alberts, P., Zahraoui, A., Louvard, D., and Galli, T. (2000). Role of tetanus neurotoxin insensitive vesicle-associated membrane protein (TI-VAMP) in vesicular transport mediating neurite outgrowth. *J Cell Biol* 149, 889-900.

- Minakaki, G., Menges, S., Kittel, A., Emmanouilidou, E., Schaeffner, I., Barkovits, K., Bergmann, A., Rockenstein, E., Adame, A., Marxreiter, F., *et al.* (2018). Autophagy inhibition promotes SNCA/alpha-synuclein release and transfer via extracellular vesicles with a hybrid autophagosome-exosome-like phenotype. *Autophagy* 14, 98-119.
- Naseri, N.N., Ergel, B., Kharel, P., Na, Y., Huang, Q., Huang, R., Dolzhanskaya, N., Burré, J., Velinov, M.T., and Sharma, M. (2020). Aggregation of mutant cysteine string protein- α via Fe-S cluster binding is mitigated by iron chelators. *Nat Struct Mol Biol* 27, 192-201.
- Nosková, L., Stránecký, V., Hartmannová, H., Přistoupilová, A., Barešová, V., Ivánek, R., Hůlková, H., Jahnová, H., van der Zee, J., Staropoli, J.F., *et al.* (2011). Mutations in DNAJC5, encoding cysteine-string protein alpha, cause autosomal-dominant adult-onset neuronal ceroid lipofuscinosis. *Am J Hum Genet* 89, 241-252.
- Ogawa, N., Hirose, Y., Ohara, S., Ono, T., and Watanabe, Y. (1985). A simple quantitative bradykinesia test in MPTP-treated mice. *Research communications in chemical pathology and pharmacology* 50, 435-441.
- Paumier, K.L., Luk, K.C., Manfredsson, F.P., Kanaan, N.M., Lipton, J.W., Collier, T.J., Steece-Collier, K., Kemp, C.J., Celano, S., Schulz, E., *et al.* (2015). Intrastriatal injection of pre-formed mouse α -synuclein fibrils into rats triggers α -synuclein pathology and bilateral nigrostriatal degeneration. *Neurobiol Dis* 82, 185-199.
- Peng, C., Trojanowski, J.Q., and Lee, V.M. (2020). Protein transmission in neurodegenerative disease. *Nat Rev Neurol*.
- Rao, S.K., Huynh, C., Proux-Gillardeaux, V., Galli, T., and Andrews, N.W. (2004). Identification of SNAREs involved in synaptotagmin VII-regulated lysosomal exocytosis. *J Biol Chem* 279, 20471-20479.
- Rasmussen, M.K., Mestre, H., and Nedergaard, M. (2018). The glymphatic pathway in neurological disorders. *Lancet Neurol* 17, 1016-1024.
- Rey, N.L., George, S., Steiner, J.A., Madaj, Z., Luk, K.C., Trojanowski, J.Q., Lee, V.M., and Brundin, P. (2018). Spread of aggregates after olfactory bulb injection of α -synuclein fibrils is associated with early neuronal loss and is reduced long term. *Acta Neuropathol* 135, 65-83.
- Rey, N.L., Petit, G.H., Bousset, L., Melki, R., and Brundin, P. (2013). Transfer of human α -synuclein from the olfactory bulb to interconnected brain regions in mice. *Acta Neuropathologica* 126, 555-573.
- Reyes, J.F., Rey, N.L., Bousset, L., Melki, R., Brundin, P., and Angot, E. (2014). Alpha-synuclein transfers from neurons to oligodendrocytes. *Glia* 62, 387-398.
- Smith, A.J., and Verkman, A.S. (2018). The "glymphatic" mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation? *Faseb j* 32, 543-551.
- Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M., and Goedert, M. (1998). alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. *Proceedings of the National Academy of Sciences of the United States of America* 95, 6469-6473.

- Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., and Goedert, M. (1997). Alpha-synuclein in Lewy bodies. *Nature* 388, 839-840.
- Sung, J.Y., Park, S.M., Lee, C.H., Um, J.W., Lee, H.J., Kim, J., Oh, Y.J., Lee, S.T., Paik, S.R., and Chung, K.C. (2005). Proteolytic cleavage of extracellular secreted {alpha}-synuclein via matrix metalloproteinases. *J Biol Chem* 280, 25216-25224.
- Velinov, M., Dolzhanskaya, N., Gonzalez, M., Powell, E., Konidari, I., Hulme, W., Staropoli, J.F., Xin, W., Wen, G.Y., Barone, R., *et al.* (2012). Mutations in the gene DNAJC5 cause autosomal dominant Kufs disease in a proportion of cases: study of the Parry family and 8 other families. *PLoS One* 7, e29729.
- Volpicelli-Daley, L.A., Luk, K.C., Patel, T.P., Tanik, S.A., Riddle, D.M., Stieber, A., Meaney, D.F., Trojanowski, J.Q., and Lee, V.M. (2011a). Exogenous α -synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. *Neuron* 72, 57-71.
- Volpicelli-Daley, L.A., Luk, K.C., Patel, T.P., Tanik, S.A., Riddle, D.M., Stieber, A., Meaney, D.F., Trojanowski, J.Q., and Lee, V.M.Y. (2011b). Exogenous α -synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. *Neuron* 72, 57-71.
- Yamada, K., and Iwatsubo, T. (2018). Extracellular α -synuclein levels are regulated by neuronal activity. *Mol Neurodegener* 13, 9.
- Yamamoto, A., and Simonsen, A. (2011). The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration. *Neurobiol Dis* 43, 17-28.
- Yee, J.K., Miyahara, A., LaPorte, P., Bouic, K., Burns, J.C., and Friedmann, T. (1994). A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. *Proc Natl Acad Sci U S A* 91, 9564-9568.